| Target Price | ¥3,340.50 |
| Price | ¥2,796.00 |
| Potential |
19.47%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Rohto Pharmaceutical Co 2027 .
The average Rohto Pharmaceutical Co target price is ¥3,340.50.
This is
19.47%
register free of charge
¥4,032.00
44.21%
register free of charge
¥2,626.00
6.08%
register free of charge
|
|
| A rating was issued by 15 analysts: 11 Analysts recommend Rohto Pharmaceutical Co to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Rohto Pharmaceutical Co stock has an average upside potential 2027 of
19.47%
register free of charge
|
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 343.73 | 373.98 |
| 11.37% | 8.80% | |
| EBITDA Margin | 14.80% | 16.85% |
| 2.62% | 13.88% | |
| Net Margin | 9.96% | 9.59% |
| 0.83% | 3.75% |
12 Analysts have issued a sales forecast Rohto Pharmaceutical Co 2027 . The average Rohto Pharmaceutical Co sales estimate is
This results in the following potential growth metrics:
12 Rohto Pharmaceutical Co Analysts have issued a net profit forecast 2027. The average Rohto Pharmaceutical Co net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 145.28 | 158.80 |
| 7.27% | 9.31% | |
| P/E | 16.96 | |
| EV/Sales | 1.60 |
12 Analysts have issued a Rohto Pharmaceutical Co forecast for earnings per share. The average Rohto Pharmaceutical Co EPS is
This results in the following potential growth metrics and future valuations:
Rohto Pharmaceutical Co...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


